NEW YORK - Wednesday, 26. February 2025 AETOSWire
ELC will step-change innovation by translating innovative anti-inflammation research into cutting-edge skin care solutions
(BUSINESS
WIRE) -- The Estée Lauder Companies Inc. (NYSE: EL) (ELC) today
announced a collaboration with biotechnology company, Serpin Pharma,
that aims to explore how their anti-inflammatory research can be applied
in cosmetics to deliver significant skin care longevity benefits to
consumers around the world.
The exclusive partnership will
accelerate ELC’s focus on transformative product innovation by applying
insights from Serpin Pharma’s two decades of anti-inflammatory research,
which has yielded proprietary biotech technology demonstrating
remarkable efficacy mitigating harmful inflammation and enhancing cell
resiliency. Serpin Pharma identified a key portion of a superfamily of
proteins called SERPINs (Serine Protease Inhibitors) that enhance the
body’s natural ability to heal cells experiencing inflammation.
Together, the companies are investigating how this innovative
technology, which leverages the body’s innate immune response, can be
harnessed to address skin irritation, aging, and sensitivity. Scientific
studies are underway to demonstrate how Serpin’s technology can be
applied to cosmetic products to rapidly and visibly reduce skin aging
and irritation.
“This novel technology will advance our
transformative innovation agenda by pushing the boundaries of
breakthrough scientific discovery,” said Carl Haney, Executive Vice
President, Global Innovation and Research and Development (R&D), The
Estée Lauder Companies. “In partnership with Serpin Pharma, we’re
exploring powerful new biological pathways and cutting-edge biotech
ingredients to rapidly mitigate visible skin irritation and sensitivity
for our prestige beauty consumers worldwide.”
“Serpin Pharma was
founded on the principles of biomimicry and how nature solves for signs
of trauma and injury,” said Cohava Gelber, PhD, MBA, Founder, Executive
Chairperson and CEO, Serpin Pharma. “We’re taking a novel approach by
tapping into the body’s innate mechanism for resolving inflammation. We
are proud to partner with ELC to explore how our powerful biotechnology
can be applied to cosmetics and skin care.”
This work builds on
ELC’s decades-long leadership in longevity science, biotechnology and
fermentation. The company is step-changing innovation by partnering with
biotech companies across sectors to commercialize their breakthrough
innovations and applying their cutting-edge technologies to developing
skin care solutions for consumers. It also reinforces ELC’s commitment
to creating transformative product innovation to deliver fast-to-market,
on-trend innovation across in-demand subcategories, benefits, and
occasions, as part of ELC’s newly unveiled Beauty Reimagined strategic
vision.
With R&D and Innovation Centers around the world,
ELC's scientists have multidisciplinary expertise ranging from basic
science and advanced technologies to the intersections of physics,
chemistry, biology, and engineering. ELC R&D has 75 years of
formulation authority and is deeply integrated into the scientific
community, regularly presenting at leading events, publishing in
peer-reviewed journals, and partnering with leading scientists,
institutions, and academia across a broad array of sectors.
About The Estée Lauder Companies
The
Estée Lauder Companies Inc. is one of the world’s leading
manufacturers, marketers, and sellers of quality skin care, makeup,
fragrance, and hair care products, and is a steward of luxury and
prestige brands globally. The company’s products are sold in
approximately 150 countries and territories under brand names including:
Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer,
Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble,
Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de
Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the
DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN
Beauty.
About Serpin Pharma, Inc
Serpin Pharma is a
trailblazing, clinical-stage pharmaceutical company committed to the
development of groundbreaking anti-inflammatory and immune-modulating
therapies aimed at effectively treating diseases driven by inflammation.
Located in Virginia, the company has engineered a remarkably small,
highly selective peptide therapeutic that boasts an astonishing
potency—300 times greater than that of its natural counterpart, Alfa-1
Antitrypsin (A1AT), in delivering anti-inflammatory and regenerative
effects.
This innovative drug platform by Serpin Pharma not only
halts unchecked inflammation without compromising the immune system but
also promotes the repair and regeneration of cells and tissues affected
by inflammation, injury, or trauma. With thirteen robust patents
securing its pipeline technologies, Serpin Pharma stands on the cusp of
pioneering breakthroughs that promise to reshape the landscape of
therapeutic treatments.
ELC-C
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225925375/en/
Permalink
https://www.aetoswire.com/en/news/2602202545029
Contacts
Alyssa Kressel
akressel@estee.com
No comments:
Post a Comment